BlueCrest Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

BlueCrest Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,338	Closed	-$520K	–	1438
2018 Q4	$520K	Buy	5,338 +3,681	+222%	+$435K	0.03%	343
2018 Q3	$230K	Buy	+1,657	New	+$208K	0.01%	1195
2018 Q1	–	Sell	-229,097	Closed	-$27.4M	–	1694
2017 Q4	$27.4M	Buy	+229,097	New	+$27.9M	0.75%	15
2016 Q1	–	Sell	-3,053	Closed	-$582K	–	1200
2015 Q4	$582K	Buy	+3,053	New	+$533K	0.02%	533
2015 Q3	–	Sell	-13,251	Closed	-$2.4M	–	1095
2015 Q2	$2.4M	Buy	+13,251	New	+$2.29M	0.07%	305

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlueCrest Capital Management's ALXN Position: Q1 2019 in Review

BlueCrest Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 5,338 shares — an estimated $520K sold.

BlueCrest Capital Management first reported a position in ALXN in Q2 2015 and held it in 5 quarters. The position peaked at $27.4M in Q4 2017. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

BlueCrest Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
BlueCrest Capital Management sold 5,338 Alexion Pharmaceuticals shares in Q1 2019, an estimated $520K.
BlueCrest Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 5 quarters.
BlueCrest Capital Management's Alexion Pharmaceuticals position peaked at $27.4M in Q4 2017.
611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on BlueCrest Capital Management's 13F filing for Q1 2019, filed 15 May 2019.